GH — Guardant Health, Inc.

GH

Guardant Health, Inc. NASDAQ

Healthcare ·Medical - Diagnostics & Research ·US · guardanthealth.com

$91.17

Mkt Cap $12.0B

52w Low $36.36 65.0% of range 52w High $120.74

50d MA $89.18 200d MA $83.57

P/E (TTM) -26.4x

EV/EBITDA -37.7x

P/B —

Debt/Equity -16.9x

ROE 419.2%

P/FCF -54.9x

RSI (14) —

ATR (14) —

Beta 1.65

50d MA $89.18

200d MA $83.57

Avg Volume 2.1M

About

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced canc…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 19, 2026	AMC	-0.77	-0.90	-17.4%	106.38	+1.5%	-3.1%	-11.2%	-10.3%	-10.4%	-7.9%	—
Oct 29, 2025	AMC	-0.48	-0.39	+18.8%	72.27	+24.5%	+27.9%	+28.7%	+36.9%	+35.8%	+31.5%	—
Jul 30, 2025	AMC	-0.52	-0.44	+15.4%	45.19	-0.7%	-9.3%	-8.3%	-2.2%	+2.2%	-1.3%	—
Apr 30, 2025	AMC	-0.61	-0.49	+19.7%	47.23	+11.5%	+3.5%	-0.8%	-6.7%	-11.2%	-15.9%	—
Feb 20, 2025	AMC	-0.75	-0.62	+17.3%	47.40	+2.3%	-9.6%	-10.5%	-14.9%	-8.9%	-11.2%	—
Nov 6, 2024	AMC	-0.55	-0.45	+18.2%	25.29	+28.1%	+13.0%	+13.1%	+16.1%	+17.6%	+25.0%	—
Aug 7, 2024	AMC	-0.57	-0.48	+15.8%	33.96	-5.6%	-10.9%	-14.6%	-10.3%	-12.4%	-14.5%	—
May 9, 2024	AMC	-0.72	-0.46	+36.1%	19.44	+10.2%	+15.1%	+23.5%	+27.2%	+32.5%	+35.0%	—
Feb 22, 2024	AMC	-0.93	-1.58	-69.9%	22.27	-5.7%	-12.8%	-9.6%	-12.3%	-15.9%	-14.7%	—
Nov 6, 2023	AMC	-0.93	-0.73	+21.5%	27.74	-2.3%	-5.4%	-14.7%	-18.9%	-22.2%	-18.4%	—
Aug 3, 2023	AMC	-1.25	-0.67	+46.4%	35.54	+2.9%	+6.4%	+5.5%	+3.7%	+2.6%	+1.5%	—
May 9, 2023	AMC	-1.26	-1.30	-3.2%	23.99	+8.3%	+14.9%	+13.0%	+9.9%	+16.3%	+13.6%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 14	Barclays	Maintains	Overweight → Overweight	—	$82.21	$83.04	+1.0%	+5.1%	+3.2%	+4.2%	+9.9%	+10.8%
Apr 6	Evercore ISI	Maintains	In Line → In Line	—	$93.83	$92.68	-1.2%	-4.4%	-0.6%	-1.1%	-7.1%	-16.2%
Feb 24	Piper Sandler	Maintains	Overweight → Overweight	—	$94.42	$95.42	+1.1%	+1.0%	+0.9%	+3.8%	-0.6%	-2.3%
Feb 20	Wells Fargo	Maintains	Overweight → Overweight	—	$106.38	$108.00	+1.5%	-3.1%	-11.2%	-10.3%	-10.4%	-7.9%
Feb 20	BTIG	Maintains	Buy → Buy	—	$106.38	$108.00	+1.5%	-3.1%	-11.2%	-10.3%	-10.4%	-7.9%
Feb 20	Leerink Partners	Maintains	Outperform → Outperform	—	$106.38	$108.00	+1.5%	-3.1%	-11.2%	-10.3%	-10.4%	-7.9%
Feb 20	Stifel	Maintains	Buy → Buy	—	$106.38	$108.00	+1.5%	-3.1%	-11.2%	-10.3%	-10.4%	-7.9%
Feb 20	Canaccord Genuity	Maintains	Buy → Buy	—	$106.38	$108.00	+1.5%	-3.1%	-11.2%	-10.3%	-10.4%	-7.9%
Feb 20	TD Cowen	Maintains	Buy → Buy	—	$106.38	$108.00	+1.5%	-3.1%	-11.2%	-10.3%	-10.4%	-7.9%
Feb 20	Evercore ISI	Maintains	In Line → In Line	—	$106.38	$108.00	+1.5%	-3.1%	-11.2%	-10.3%	-10.4%	-7.9%
Feb 20	JP Morgan	Maintains	Overweight → Overweight	—	$106.38	$108.00	+1.5%	-3.1%	-11.2%	-10.3%	-10.4%	-7.9%
Feb 20	Citigroup	Maintains	Buy → Buy	—	$106.38	$108.00	+1.5%	-3.1%	-11.2%	-10.3%	-10.4%	-7.9%
Jan 26	Guggenheim	Maintains	Buy → Buy	—	$114.75	$114.15	-0.5%	-0.0%	-0.1%	-4.4%	-3.7%	-0.6%
Jan 9	Stifel	Maintains	Buy → Buy	—	$108.74	$108.17	-0.5%	+1.3%	-1.1%	-1.7%	-0.1%	+3.0%
Jan 5	Guggenheim	Maintains	Buy → Buy	—	$101.74	$101.10	-0.6%	+0.1%	+10.4%	+8.0%	+6.9%	+8.3%
Jan 5	Evercore ISI	Downgrade	Outperform → In Line	—	$101.74	$101.10	-0.6%	+0.1%	+10.4%	+8.0%	+6.9%	+8.3%
Dec 22	Canaccord Genuity	Maintains	Buy → Buy	—	$99.74	$100.93	+1.2%	+1.6%	+2.8%	+2.6%	+3.2%	+1.7%
Dec 17	Mizuho	Maintains	Outperform → Outperform	—	$100.00	$101.46	+1.5%	-2.5%	-2.9%	-0.3%	+1.3%	+2.5%
Dec 15	Wells Fargo	Maintains	Overweight → Overweight	—	$102.07	$104.12	+2.0%	+0.6%	-2.0%	-4.5%	-4.9%	-2.3%
Dec 15	JP Morgan	Maintains	Overweight → Overweight	—	$102.07	$104.12	+2.0%	+0.6%	-2.0%	-4.5%	-4.9%	-2.3%
Dec 15	Leerink Partners	Maintains	Outperform → Outperform	—	$102.07	$104.12	+2.0%	+0.6%	-2.0%	-4.5%	-4.9%	-2.3%
Dec 15	Barclays	Maintains	Overweight → Overweight	—	$102.07	$104.12	+2.0%	+0.6%	-2.0%	-4.5%	-4.9%	-2.3%
Dec 12	BTIG	Maintains	Buy → Buy	—	$101.38	$103.52	+2.1%	+0.7%	+1.3%	-1.4%	-3.9%	-4.2%
Dec 11	Citigroup	Maintains	Buy → Buy	—	$102.62	$104.36	+1.7%	-1.2%	-0.5%	+0.0%	-2.6%	-5.0%
Dec 2	Morgan Stanley	Maintains	Overweight → Overweight	—	$105.22	$106.62	+1.3%	-1.3%	+0.7%	+3.1%	-3.0%	-1.0%
Oct 30	UBS	Maintains	Buy → Buy	—	$72.27	$89.99	+24.5%	+27.9%	+28.7%	+36.9%	+35.8%	+31.5%
Oct 30	BTIG	Maintains	Buy → Buy	—	$72.27	$89.99	+24.5%	+27.9%	+28.7%	+36.9%	+35.8%	+31.5%
Oct 30	Citigroup	Maintains	Buy → Buy	—	$72.27	$89.99	+24.5%	+27.9%	+28.7%	+36.9%	+35.8%	+31.5%
Oct 30	Canaccord Genuity	Maintains	Buy → Buy	—	$72.27	$89.99	+24.5%	+27.9%	+28.7%	+36.9%	+35.8%	+31.5%
Oct 30	Barclays	Maintains	Overweight → Overweight	—	$72.27	$89.99	+24.5%	+27.9%	+28.7%	+36.9%	+35.8%	+31.5%
Oct 30	Evercore ISI	Maintains	Outperform → Outperform	—	$72.27	$89.99	+24.5%	+27.9%	+28.7%	+36.9%	+35.8%	+31.5%
Oct 22	Piper Sandler	Maintains	Overweight → Overweight	—	$67.51	$69.23	+2.5%	+0.8%	+2.7%	+6.9%	+4.9%	+3.1%
Oct 7	Evercore ISI	Maintains	Outperform → Outperform	—	$63.38	$63.27	-0.2%	+0.1%	+3.1%	+3.0%	+1.3%	-2.6%
Oct 2	Barclays	Maintains	Overweight → Overweight	—	$62.65	$62.60	-0.1%	-1.9%	+0.3%	+1.2%	+1.3%	+4.3%
Sep 26	Canaccord Genuity	Maintains	Buy → Buy	—	$60.18	$60.18	+0.0%	-0.2%	+3.0%	+3.8%	+4.1%	+2.1%
Sep 25	Wolfe Research	Upgrade	Peer Perform → Outperform	—	$57.67	$59.37	+2.9%	+4.4%	+4.1%	+7.5%	+8.3%	+8.6%
Sep 25	Stifel	Maintains	Buy → Buy	—	$57.67	$59.37	+2.9%	+4.4%	+4.1%	+7.5%	+8.3%	+8.6%
Sep 25	UBS	Maintains	Buy → Buy	—	$57.67	$59.37	+2.9%	+4.4%	+4.1%	+7.5%	+8.3%	+8.6%
Sep 25	TD Cowen	Maintains	Buy → Buy	—	$57.67	$59.37	+2.9%	+4.4%	+4.1%	+7.5%	+8.3%	+8.6%
Sep 25	Leerink Partners	Maintains	Outperform → Outperform	—	$57.67	$59.37	+2.9%	+4.4%	+4.1%	+7.5%	+8.3%	+8.6%
Sep 25	JP Morgan	Maintains	Overweight → Overweight	—	$57.67	$59.37	+2.9%	+4.4%	+4.1%	+7.5%	+8.3%	+8.6%
Sep 25	BTIG	Maintains	Buy → Buy	—	$57.67	$59.37	+2.9%	+4.4%	+4.1%	+7.5%	+8.3%	+8.6%
Sep 25	Mizuho	Maintains	Outperform → Outperform	—	$57.67	$59.37	+2.9%	+4.4%	+4.1%	+7.5%	+8.3%	+8.6%
Sep 25	Guggenheim	Maintains	Buy → Buy	—	$57.67	$59.37	+2.9%	+4.4%	+4.1%	+7.5%	+8.3%	+8.6%
Sep 22	BTIG	Maintains	Buy → Buy	—	$59.15	$59.80	+1.1%	+1.1%	+1.0%	-2.5%	+1.7%	+1.5%
Sep 4	BTIG	Maintains	Buy → Buy	—	$65.06	$60.00	-7.8%	-5.7%	-7.6%	-7.5%	-8.6%	-13.0%
Jul 31	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$45.19	$44.86	-0.7%	-9.3%	-8.3%	-2.2%	+2.2%	-1.3%
Jul 31	Raymond James	Maintains	Outperform → Outperform	—	$45.19	$44.86	-0.7%	-9.3%	-8.3%	-2.2%	+2.2%	-1.3%
Jun 13	Mizuho	Maintains	Outperform → Outperform	—	$49.02	$47.22	-3.7%	+0.6%	+0.6%	+1.0%	+3.2%	+0.2%
May 6	Piper Sandler	Maintains	Overweight → Overweight	—	$44.05	$43.30	-1.7%	-4.8%	-9.8%	-5.4%	-5.3%	-5.4%

Recent Filings

8-K

Guardant Health, Inc. -- 8-K Filing

Guardant Health filed an 8-K with the SEC, likely containing material events or updates affecting the oncology diagnostics company that investors should monitor for potential impacts on stock performance.

Apr 27

8-K

Guardant Health, Inc. -- 8-K Filing

Guardant Health delivered 39% revenue growth in Q4 2025 across oncology and screening, guiding 2026 revenue growth of 27-30%, signaling sustained expansion but moderating growth rate.

Feb 19

Data updated apr 25, 2026 11:20am · Source: massive.com